# Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
Canonical URL: https://biopharmsignal.com/news/MNPR/monopar-announces-alxn1840-data-selected-for-late-breaker-presentation-at-easl-congress-2025
Ticker: MNPR
Company: Monopar
Source: Monopar
Published: 2025-04-29 12:00 EST
Original Source URL: https://ir.monopartx.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-22 12:00 EST — [Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease](https://biopharmsignal.com/news/MNPR/monopar-initiates-rolling-nda-submission-for-alxn1840-in-wilson-disease-e671ddcf) — Source: Monopar
- 2026-07-20 12:00 EST — [Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team](https://biopharmsignal.com/news/MNPR/monopar-advances-launch-readiness-with-addition-of-veteran-commercial-executive--6af36ead) — Source: Monopar
- 2026-06-30 12:00 EST — [Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease](https://biopharmsignal.com/news/MNPR/monopar-therapeutics-receives-fda-rare-pediatric-disease-designation-for-alxn184-4666946b) — Source: Monopar
- 2026-06-26 20:05 EST — [Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease](https://biopharmsignal.com/news/MNPR/monopar-presents-new-analyses-of-phase-3-focus-data-at-ean-2026-showing-greater--6b830c10) — Source: Monopar
- 2026-06-01 11:00 EST — [Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026](https://biopharmsignal.com/news/MNPR/monopar-presents-phase-2-alxn1840-data-demonstrating-liver-disease-stabilization-and-neurologic-improvement-in-treatment-experienced-wilson-disease-patients-at-easl-2026) — Source: Monopar
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)